{"id":136239,"date":"2025-12-04T10:01:23","date_gmt":"2025-12-04T09:01:23","guid":{"rendered":"https:\/\/www.bcfi.be\/?post_type=avada_portfolio&#038;p=136239"},"modified":"2026-03-17T13:36:52","modified_gmt":"2026-03-17T12:36:52","slug":"gliflozines-inhibiteurs-du-sglt2-dans-le-diabete-de-type-2","status":"publish","type":"avada_portfolio","link":"https:\/\/beta.cbip.be\/fr\/portfolio\/gliflozines-inhibiteurs-du-sglt2-dans-le-diabete-de-type-2\/","title":{"rendered":"Gliflozines (inhibiteurs du SGLT2) dans le diab\u00e8te de type 2"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>Ces derni\u00e8res ann\u00e9es, les inhibiteurs du SGLT2 ont pris une place plus importante dans diff\u00e9rentes recommandations relatives au diab\u00e8te de type 2. Mais comment int\u00e9grer cela dans votre pratique quotidienne ?<\/p>\n<p>\u00c0 l&rsquo;aide de cas concrets et de deux petits jeux interactifs, vous apprendrez :<\/p>\n<ul>\n<li>quels patients peuvent tirer profit des gliflozines et chez qui vaut-il mieux les \u00e9viter ;<\/li>\n<li>comment commencer un traitement par gliflozines en toute s\u00e9curit\u00e9 et \u00e0 quoi faire attention lors du suivi ;<\/li>\n<li>quels sont les principaux risques et comment \u00e9viter les complications.<\/li>\n<\/ul>\n<p>Vous recevrez \u00e9galement un bref r\u00e9sum\u00e9 ainsi qu&rsquo;une fiche d&rsquo;information destin\u00e9e aux patients, que vous pourrez utiliser directement dans votre pratique.<\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#9201; <b>30&prime;<\/b><br \/>Ce que tout m\u00e9decin traitant et pharmacien doit savoir pour une utilisation s\u00fbre de ces m\u00e9dicaments.<br \/><b>M\u00e9decins: 0.5 CP, Pharmacien d&rsquo;officine: 1 CP, Pharmacien hospitalier: 1 CP<\/b><br \/>&#9202; d\u00e9cembre 2025<\/p>\n","protected":false},"author":13,"featured_media":136241,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"portfolio_category":[30,32],"portfolio_skills":[15,16,141],"portfolio_tags":[20347,20348,20349],"class_list":["post-136239","avada_portfolio","type-avada_portfolio","status-publish","format-standard","has-post-thumbnail","hentry","portfolio_category-pour-les-medecins","portfolio_category-pour-les-pharmaciens","portfolio_skills-medecin-0-5-cp","portfolio_skills-pharmacien-dofficine-1-cp","portfolio_skills-pharmacien-hospitalier-1-cp","portfolio_tags-antidiabetique","portfolio_tags-inhibiteurs-du-sglt2","portfolio_tags-gliflozines"],"_links":{"self":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/avada_portfolio\/136239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/avada_portfolio"}],"about":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/types\/avada_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=136239"}],"version-history":[{"count":6,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/avada_portfolio\/136239\/revisions"}],"predecessor-version":[{"id":180099,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/avada_portfolio\/136239\/revisions\/180099"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/media\/136241"}],"wp:attachment":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=136239"}],"wp:term":[{"taxonomy":"portfolio_category","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/portfolio_category?post=136239"},{"taxonomy":"portfolio_skills","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/portfolio_skills?post=136239"},{"taxonomy":"portfolio_tags","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/portfolio_tags?post=136239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}